VALLEY FORGE, Pa.--(BUSINESS WIRE)--July 14,
2003--AmerisourceBergen Corporation (NYSE:ABC), the largest
pharmaceutical services company in the U.S. dedicated solely to the
pharmaceutical supply channel, today announced the completion of a
$1.05 billion securitization program for the Company's trade
receivables. The new program provides $550 million under a three-year
revolving tranche and $500 million under a 364-day revolving tranche.
The new program replaces two separate securitization programs,
which the Company inherited from its two previous companies at the
time of the August 2001 merger that created AmerisourceBergen.
About AmerisourceBergen
AmerisourceBergen (NYSE:ABC) is the largest pharmaceutical
services company in the United States dedicated solely to the
pharmaceutical supply chain. It is the leading distributor of
pharmaceutical products and services to the hospital systems/acute
care market, physician's offices, alternate care and mail order
facilities, independent community pharmacies, and regional chain
pharmacies. The Company is also a leader in the long term care
pharmacy and workers' compensation fulfillment marketplaces. With more
than $40 billion in annualized operating revenue, AmerisourceBergen is
headquartered in Valley Forge, PA, and employs more than 13,000
people. AmerisourceBergen is ranked #24 on the Fortune 500 list and
was ranked #6 in the 2003 Business Week 50, a list of the 50 best
performing companies in the S & P 500. For more information, go to
www.amerisourcebergen.com.
Forward-Looking Statements
This news release may contain certain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. These statements
are based on management's current expectations and are subject to
uncertainty and changes in circumstances. Actual results may vary
materially from the expectations contained in the forward-looking
statements. Forward-looking statements may include statements
addressing future financial and operating results of AmerisourceBergen
and the benefits and other aspects of the 2001 merger between
AmeriSource Health Corporation and Bergen Brunswig Corporation.
The following factors, among others, could cause actual results to
differ materially from those described in any forward-looking
statements: competitive pressures; the loss of one or more key
customer relationships; customer insolvencies; changes in customer
mix; changes in pharmaceutical manufacturers' pricing and distribution
policies; regulatory changes; changes in U.S. government policies;
failure to integrate the businesses of AmeriSource and Bergen Brunswig
successfully; failure to obtain and retain expected synergies from the
merger of AmeriSource and Bergen Brunswig; and other economic,
business, competitive, regulatory and/or operational factors affecting
the business of AmerisourceBergen generally.
More detailed information about these factors is set forth in
AmerisourceBergen's filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for fiscal 2002.
AmerisourceBergen is under no obligation to (and expressly
disclaims any such obligation to) update or alter any forward looking
statements whether as a result of new information, future events or
otherwise.
CONTACT: AmerisourceBergen Corporation, Valley Forge
Michael N. Kilpatric, 610-727-7118
mkilpatric@amerisourcebergen.com
SOURCE: AmerisourceBergen Corporation